Quick Answer
Contineum Therapeutics, Inc. reported Stockholders Equity of $260.99 million for the year ending 2025.
- Contineum Therapeutics, Inc. showed an increase of +31.8% in Stockholders Equity from 2024 to 2025.
- This data is from Contineum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$97.46 million | Q2 2023: -$55.43 million | Q3 2023: -$61.15 million | Q1 2024: -$75.63 million | Q2 2024: $217.50 million | Q3 2024: $210.23 million | Q1 2025: $184.77 million | Q2 2025: $171.39 million | Q3 2025: $180.47 million.
- Over the full 4 years of available data (2022 to 2025), Contineum Therapeutics, Inc.'s Stockholders Equity has grown by 380.0%.
- Historical annual values: Fiscal year 2025: $260.99 million | Fiscal year 2024: $198.07 million | Fiscal year 2023: -$67.94 million | Fiscal year 2022: -$93.21 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: